I am going to be straightforward about something that a lot of people in the community are doing but few are willing to discuss openly: I used compounded tirzepatide because I could not afford the brand-name version.
Background: BMI 36, no diabetes, so insurance would not cover Mounjaro. Zepbound was not approved yet when I started. Cash price through my pharmacy: $1,050 per month. I make $58,000 a year. That is not a real option.
A friend told me about telehealth services that prescribe compounded tirzepatide through 503A compounding pharmacies. During the FDA shortage listing, this was legal. I paid $350 per month for a 4-week supply of 10mg vials, which I drew up and injected myself using insulin syringes.
The experience: It worked. The appetite suppression was real. The nausea was real. The weight loss was real — 28 lbs in four months. I experienced the same side effect profile that brand-name users describe.
The concerns: I was anxious the entire time. Compounded peptides are not subject to the same manufacturing standards as FDA-approved products. There is no guarantee of sterility, potency, or purity. I was injecting a substance into my body that was mixed in a pharmacy I had never visited, prescribed by a doctor I met via video call for 8 minutes. Every time I drew up a dose, a small voice asked whether this particular vial was properly compounded.
I got regular bloodwork. My A1C improved, my liver enzymes were normal, no red flags. But I was aware that I was taking a calculated risk.
When Eli Lilly resolved the shortage and the FDA began questioning whether compounded tirzepatide should remain available, I switched to brand-name Zepbound through a savings card program that brought my cost to $550/month. Still painful, but I sleep better knowing exactly what is in the vial.
I share this because the access and cost issue is the elephant in the room. Tens of thousands of people are using compounded versions because the pharmaceutical pricing model excludes them. That is not a medical story — it is a policy failure.